EQUUS RECEIVES NOTICE OF NON-COMPLIANCE WITH NEW YORK STOCK EXCHANGE SHARE PRICE RULE
EQUUS TOTAL RETURN, INC. (EQS) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Contact: Equus Total Return, Inc. 1-888-323-4533 EQUUS RECEIVES NOTICE OF NON-COMPLIANCE WITH NEW YORK STOCK EXCHANGE SHARE PRICE RULE Company Intends to Regain Compliance with NYSE Rule Notice Has No Immediate Impact on the Listing or Trading of Equus Common Stock H
How this was made
The 30-second read
Why it matters
The company intends to cure the deficiency within the NYSE cure period and may consider alternatives including a reverse stock split; failure to cure would raise delisting risk later, but the current notice does not affect trading immediately.
Market read
This is a compliance-driven catalyst that can change near-term valuation expectations and increase volatility until the $1.00 average-price condition is met.
What to watch
Traders should focus on the company’s ability to engineer a sustained $1.00+ average closing price by month-end during the cure period, not just the headline deficiency.
Background
Equus Total Return, Inc. received an NYSE notice of deficiency under Section 802.01C for failing the minimum average closing price requirement.
Ticker impact
Equus disclosed NYSE non-compliance for average closing price below $1.00 over 30 trading days, with a cure plan and possible reverse split.
Likely downside or volatility as traders price the probability/timing of a reverse split and the chance the company fails to cure within the allowed window.
The filing is a primary NYSE deficiency notice (not delisting) but it explicitly flags a compliance deadline and a potential reverse split, which typically pressures small-cap closed-end fund valuations and liquidity.
Market effects
Highlights ongoing NYSE $1.00 price compliance risk for closed-end funds and other low-priced small caps, potentially increasing sector-wide caution on similar issuers.
Primarily US-listed small-cap sentiment; limited spillover beyond NYSE-listed micro/small-cap universe.
Low, as the catalyst is NYSE listing compliance specific to the issuer.
Counterpoint
Because the notice is explicitly not delisting and states no immediate impact on listing or trading, the market may overreact relative to the actual probability of a near-term forced exit.
Key entities
- companyEquus Total Return, Inc.
NYSE-listed closed-end business development company that received an NYSE share price non-compliance notice.
- exchangeNew York Stock Exchange (NYSE)
Exchange that issued the notice of deficiency under its continued listing price rule.
